SEC Filing Summary: Athira Pharma, Inc. (ATHA)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. on April 15, 2025. The report addresses a corporate governance and listing status event regarding the company's common stock on The Nasdaq Stock Market. The filing details the approval of a transfer of the company's listing from the Nasdaq Global Select Market to the Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding listing status and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric referenced is the minimum bid price requirement of $1.00 per share, which the company failed to maintain for 30 consecutive business days prior to October 16, 2024.
Material Changes and Listing Status
- Listing Transfer Approved: Nasdaq approved the transfer of Athira Pharma's common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market.
- Effective Date: The transfer became effective at the opening of business on April 17, 2025.
- Trading Symbol: The stock will continue to trade under the symbol "ATHA."
- Reason for Transfer: The company was non-compliant with the minimum bid price requirement ($1.00 per share) for the Global Select Market. The transfer was requested to secure an additional compliance period.
- Compliance Timeline: The company has been granted an additional 180-day grace period, extending until October 13, 2025, to regain compliance.
Outlook, Risks, and Management Commentary
Management is seeking stockholder approval to effect a reverse stock split at the 2025 annual meeting of stockholders as a mechanism to regain compliance with the minimum bid price requirement. The filing includes standard forward-looking statements regarding the company's intent to meet listing standards.
Key Risks and Contingencies:
- Delisting Risk: If the company fails to maintain a minimum bid price of at least $1.00 for at least ten consecutive business days during the additional 180-day grace period, its common stock will be subject to delisting by Nasdaq.
- Reverse Split Uncertainty: There is no guarantee that the proposed reverse stock split will be approved by stockholders or successfully implemented.
- Market Conditions: Actual results may differ materially from expectations due to market volatility and the company's ability to meet Nasdaq listing rules.
Investor Verification Checklist
- Verify the outcome of the 2025 annual meeting of stockholders regarding the proposed reverse stock split.
- Monitor the daily closing bid price of ATHA to ensure it meets the $1.00 threshold for ten consecutive business days before October 13, 2025.
- Review the company's most recent Form 10-K (filed February 27, 2025) and subsequent 10-Q filings for detailed financial health and liquidity status, as this 8-K does not contain such data.
- Confirm that the stock continues to trade under the symbol "ATHA" on the Nasdaq Capital Market post-transfer.